Merus to Participate in Upcoming Investor Conferences

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in the following investor conferences:

• Citi's 2023 18th Annual BioPharma Conference (fireside chat): Thursday, September 7 at 2:40-3:25 p.m. ET
• Morgan Stanley 21st Annual Global Healthcare Conference: Wednesday, September 13 12:55-1:25 p.m. ET

The webcasts of the presentations will be contemporaneously available on the Investors page of the Company's website. Archived presentations will also be available there for a limited time after the event.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.

Multiclonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V.

You May Also Be Interested In

• Taiwan AI Island at InfoComm 2026 Spotlights Taiwan's Shift from Hardware Manufacturing to Software-Defined Pro AV
• The DEA Marijuana Hearing Starts June 29. the Real Rescheduling Fight is Already in the D.C. Circuit.
• Kraken Robotics Announces 2026 Annual and Special Meeting Results